*Low cardiac events occurrence defined as 5.2% for bosutinib cf 5.3% for imatinib in clinical trials.2
Data from adult patients with newly diagnosed CML, comparing BOSULIF with imatinib
Review the long-term efficacy and safety data for adult patients with newly diagnosed CML
Access long-term efficacy and safety data in patients recieving BOSULIF in second-line and onwards
Access long-term efficacy and safety data in patients recieving second-line BOSULIF
Review the Phase 4 trial, evaluating the safety & efficacy of BOSULIF in patients with CP or AP Ph+ CML who have failed prior treatment with TKIs
400mg BOSULIF for adult patients with newly-diagnosed chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukaemia (Ph+ CML)
500mg BOSULIF for adult patients with CP, accelerated phase (AP), and blast phase (BP) Ph+ CML previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options
100mg BOSULIF for dose escalation and reduction in increments between 300mg and 600mg (known as range of efficacy), depending on patient response and tolerability. Please refer to Summary of Product Characteristics for full guidance on when to escalate or reduce BOSULIF dosing by 100mg increments.
For information on dosing and dose adjustments, view Dosing Guide
Colour and size of tablets shown are not representative of the actual tablets and are for illustrative purposes only. 100 mg tablets width: 5.6 mm, length: 10.7 mm; 400 mg tablets width: 8.8 mm, length: 16.9 mm; 500 mg tablets width: 9.5 mm, length: 18.3 mm.1
AP, accelerated phase; BP, blast phase; CML, chronic myelogenous leukaemia; CP, chronic phase; Ph+ CML; Philadelphia chromosome-positive chronic myelogenous leukaemia, TKI; tyrosine kinase inhibitor.
References:
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024